Burke W J, Roccaforte W H, Wengel S P, Bayer B L, Ranno A E, Willcockson N K
Department of Psychiatry, University of Nebraska Medical Center, Omaha 68198-5575.
J Am Geriatr Soc. 1993 Nov;41(11):1219-25. doi: 10.1111/j.1532-5415.1993.tb07306.x.
To examine the cognitive and behavioral effects of L-deprenyl in persons with mild dementia of the Alzheimer type (DAT) over a 15-month period.
A 15-month randomized, double-blind, placebo-controlled trial using a parallel-group design.
39 subjects with mild DAT (CDR 1) selected using NINCDS-ADRDA criteria.
A battery of neuropsychological tests and clinical rating scales.
The placebo and L-deprenyl subjects were similar at baseline on the clinical and neuropsychological tests. The total score on the Brief Psychiatric Rating Scale (BPRS) was significantly less after 15 months in subjects taking L-deprenyl. The only individual item of the BPRS which differed between groups was disorientation. There was no evidence of a L-deprenyl effect on any other clinical or neuropsychological measure after 2, 8, or 15 months.
L-deprenyl did appear to have a slight effect on a single measure of psychopathology, the BPRS. It did not have a measurable impact on any other measure of behavior or cognitive function over a 15-month period in this group of subjects with mild DAT and did not appear to slow the progression of the disease.
在15个月的时间里，研究左旋司来吉兰对轻度阿尔茨海默型痴呆（DAT）患者认知和行为的影响。
采用平行组设计的15个月随机、双盲、安慰剂对照试验。
根据NINCDS-ADRDA标准选取39名轻度DAT（临床痴呆评定量表[CDR]评分为1）患者。
一系列神经心理学测试和临床评定量表。
在临床和神经心理学测试方面，安慰剂组和左旋司来吉兰组在基线时相似。服用左旋司来吉兰的患者在15个月后，简明精神病评定量表（BPRS）总分显著降低。两组间BPRS中唯一有差异的单项是定向障碍。在2个月、8个月或15个月后，没有证据表明左旋司来吉兰对任何其他临床或神经心理学指标有影响。
左旋司来吉兰似乎仅对精神病理学的一项指标BPRS有轻微影响。在这组轻度DAT患者中，在15个月的时间里，它对任何其他行为或认知功能指标均无显著影响，且似乎并未减缓疾病进展。
